Status:
RECRUITING
Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations
Lead Sponsor:
Shandong University
Collaborating Sponsors:
Shandong Provincial Hospital
Conditions:
Early-Onset Neonatal Sepsis
Eligibility:
FEMALE
18+ years
Brief Summary
The purpose of this study is to describe the population pharmacokinetic characteristics of piperacillin/tazobactam after intravenous administration in pregnant women during pregnancy and delivery, and...
Eligibility Criteria
Inclusion
- Patients over 18 years old;
- Pregnant women whose baby are at high risk of developing early-onset sepsis after birth have indications to use preventive or therapeutic antibiotics, and the antibiotics used are PIP/TAZO；
- Patients and their families are fully aware of the research content and sign the informed consent form.
Exclusion
- Intolerance or serious adverse reactions to antibiotic use;
- Patients who stopped using PIP/TAZO more than 24 hours before delivery;
- Receiving other systemic trial drugs;
- There are other factors that the researchers think are not suitable for inclusion
Key Trial Info
Start Date :
September 30 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06076200
Start Date
September 30 2023
End Date
December 31 2026
Last Update
October 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shandong Provincial Hospital
Jinan, China